Corteva (CTVA): What This Company Actually Does

How Corteva makes money

Corteva sells farmers high-performing corn and soybean seeds and the agrochemicals that protect those crops from weeds, insects, and disease. In the U.S., independent sales agents sell direct to farmers under the Pioneer brand; elsewhere, the company relies on retail, distributor, and cooperative networks.

Revenue reinvested into R&D feeds next year's new seed varieties and chemistry pipeline; the rest is split between shareholder returns (dividends and buybacks) and the business. A bad growing season or a delayed new product launch disrupts this whole cycle.

Where the revenue comes from

Source: 10-K FY2025, p.F-66 (Note 22, Segment Information).

Geographically (2025, by customer location): the U.S. is 47.5%, Latin America 22.6% (including Brazil at 16.7 points), EMEA 17.9%, Asia-Pacific 7.7%, and Canada 4.3%. With international revenue at 52.5% of the total, Corteva is exposed to currency swings (Brazilian real, euro) and country-specific regulatory risk.

Source: 10-K FY2025, p.F-64 (Note 21, Geographic Information).

Customers and competitors

Customers are individual farms and distributors worldwide — no single customer accounts for a meaningful concentration of revenue.

• Bayer — the world's largest seed and agrochemical company (Crop Science segment), with the scale from its Monsanto acquisition to combine seed and chemistry more tightly than Corteva can.
• Syngenta — owned by China's ChemChina, particularly strong in crop-protection chemicals and backed by Chinese government capital.
• BASF — the agricultural solutions arm of the German chemicals giant, with cost advantages from vertically integrated chemical raw materials.

Source: 10-K FY2025, p.8 (Competition).

The metric that matters most in this sector

Segment operating EBITDA margin is the top metric Corteva's own chief operating decision-maker uses to judge business performance — it shows whether revenue growth is actually translating into profit after commodity and labor costs, rather than just getting eaten up by them.

Both segments improved margins in 2025, and the growth wasn't just price-driven: FY2025 revenue grew from +1% price, +3% volume, and -1% currency — a genuinely broader-based improvement, not one propped up by price hikes alone.

Source: 10-K FY2025, p.F-66; p.31 (price/volume/currency breakdown).

Leadership and ownership

CEO Charles (Chuck) V. Magro has led the company since November 2021 (about 4 years), with a long agricultural-industry background as former CEO of fertilizer companies Nutrien and Agrium. He is not a founder — Corteva itself was spun off from DowDuPont in 2019. Combined insider ownership is about 0.15%, very low. The largest shareholders are Vanguard (12.0%), BlackRock (8.0%), and State Street (5.3%).

Source: DEF 14A 2026, executive bios and ownership tables.

Capital returns

Corteva pays $0.72/share annually ($0.18/quarter), yielding about 0.9% at the current price, with a payout ratio around 44-51%. It raised the quarterly dividend 6% (from $0.17 to $0.18) in July 2025, continuing a steady increase from $0.66/share (FY2024) to $0.70 (FY2025).

Buybacks totaled $2,836M over the past three years (FY2023-2025), and unlike some peers, this actually reduced the share count: shares outstanding fell steadily from 713.41 million (end of 2022) to 672.16 million (end of 2025) — genuine shareholder returns, not offset by new share issuance.

Source: 10-K FY2025, p.28, 31 (dividend); stockanalysis.com (Aug 28, 2026 quote); 10-K FY2025, p.F-7, F-8 (share count).

How this company could fail

• Separation (spinoff) execution risk — the planned split of Seed and Crop Protection into two companies, targeted for completion by late 2026, still has unresolved details around tax-free treatment, final capital structure, and separation costs. If it doesn't go as planned or is delayed, both resulting companies' valuations could be affected.
• Regulatory approval delays — new seed traits and chemicals require government approval (in the U.S., the EPA, USDA, and FDA), and recent staffing and budget cuts at these agencies raise the risk of slower approvals, which directly delays new-product revenue.
• Weather and climate volatility — droughts and heavy rains simultaneously affect that year's seed production and quality, and crop-protection demand — a variable entirely outside Corteva's control that directly hits results.

Source: 10-K FY2025, p.22-23 (separation risk), p.11, 14 (regulatory risk), p.13 (weather risk).

Five-year financials

Operating income = revenue minus cost of sales, R&D, SG&A, intangible amortization, and restructuring/separation costs (10-K FY2025 p.F-5, FY2023 10-K p.F-5). FCF = operating cash flow minus capex (10-K FY2025 p.F-8, FY2023 10-K p.F-8). Debt = short-term borrowings plus long-term debt (10-K FY2025 p.F-7, FY2023/FY2022 10-K p.F-7).

What we still don't know

• The exact capital structure, dividend policy, and listing tickers of the two post-separation companies haven't been disclosed yet — a Form 10 registration statement will need to be filed first.
• How results since Q2 2026 are tracking against annual guidance can't be determined from this data alone — recent earnings calls would need to be checked.
• How the U.S. FTC/DOJ antitrust investigation into the seed industry (following a December 2025 executive order) will conclude is still ongoing and unknown.